Rivastigmine (Exelon) For Alzheimer's Disease
Rivastigmine tartrate (Exelon - Novartis), a carbamate-based cholinesterase inhibitor, is now being marketed for treatment of patients with dementia due to Alzheimer's disease....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rivastigmine (Exelon) For Alzheimer's Disease
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1089
Article Code: 1089a
Date: October 2, 2000
Volume: 42
Pages: 93-94
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1089
Article Code: 1089a
Date: October 2, 2000
Volume: 42
Pages: 93-94
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)